Income Statement
UNICYCIVE THERAPEUTICS, INC.
UNCY
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | 0.68 | 0.95 | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | 0.68 | 0.95 | - |
|
Operating Expenses
|
29.52 | 32.12 | 21.45 | 19.00 | 8.98 |
|
Research & Development
|
9.12 | 20.01 | 12.90 | 12.44 | 6.08 |
|
Selling, General & Administrative
|
20.40 | 12.10 | 8.55 | 6.57 | 2.90 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-29.52 | -32.12 | -20.77 | -18.05 | -8.98 |
|
Non-Operating Income
|
2.96 | -4.61 | - | -0.01 | -1.04 |
|
Interest Income
|
1.01 | 1.26 | 0.62 | - | - |
|
Interest Expense
|
- | - | 0.08 | 0.01 | 0.63 |
|
Other Non-Op Income / Expense
|
- | - | -9.77 | - | - |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-26.56 | 36.73 | -30.54 | -18.06 | -10.02 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-29.52 | -32.12 | -20.77 | -18.05 | -8.98 |
|
Earnings Per Share (Basic)
|
-1.67 | -0.56 | -1.28 | -1.20 | -0.86 |
|
Diluted EPS
|
-1.67 | -0.56 | -1.28 | -1.20 | - |
|
Weighted Average Shares
|
15.89 | 66.99 | 24.54 | 15.06 | 11.68 |
|
Diluted Weighted Avg Shares
|
15.89 | 66.99 | 24.54 | 15.06 | - |
|
Comprehensive Income
|
-26.56 | - | - | - | - |